Abstract 436P
Background
With the advent of personalized medicine, recent clinical trials have placed much emphasis on the OS and PFS of cancer patients. However, several international guidelines also emphasize the need for assessing the Health Related Quality of Life (HRQoL) as part of our holistic approach in the management of cancer patients. This study evaluated the present status of the Filipino oncologists’ approach in assessing the quality of life of cancer patients.
Methods
This was a cross-sectional study that utilized a survey questionnaire. Participants included physicians in the care of the cancer patient (consultants & trainees) – medical, surgical, radiation, gynecologic oncologists, and hematologists, who were contacted via email through the database of their respective societies, and personally during scientific meetings / conferences. Descriptive and multivariate analysis were used to analyze the data.
Results
312 oncologists participated. 96% reported that HQRoL assessment was important for clinical work, however 58% perceived HRQoL to be a vague term; 69% agreed that verbal HRQoL assessments were generally enough, and 39% reported that their patients did not accept HRQoL questionnaires. Furthermore, 78% did not know which HRQoL assessment tool to use, and that the questionnaires were too extensive and too lengthy for routine use; 55% reported that they did not feel sufficiently trained to assess HRQoL. About 89.42% reported that they will be more confident if local HRQoL assessment guidelines will be present, and 92.95% agreed to the use of a unified HRQoL assessment tool for Filipino cancer patients.
Conclusions
Filipino oncologists perceived HRQoL patient assessments to be important in clinical practice. However, majority did not know which tool to use and did not feel sufficiently trained to assess HRQoL. The creation of a practice guideline that would facilitate the use of a unified HRQoL assessment tool (containing 5-15 questions) for Filipino cancer patients will be explored.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract